The drug for treatment of dandruff :: Consumers survey results of 2017

Consumers survey results of 2017 in category

Dermatology, means for external use / The drug for treatment of dandruff

The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.

	I quarter (january—march)
	II quarter (april—june)
	III quarter (july—september)
	IV quarter (october—december)

1.		Сульсена (Амальгама Люкс)	46.15%	5

2.	3	Nizoral (Janssen)	32.31%	3.43

3.	2	Дермазол (Kusum Pharm)	26.15%	2.83

4.		Кетозорал (Darnitsa)	16.92%	1.85

5.	6	Кеназол (Pharma International)	13.85%	1.50

6.	5	Ламікон (Farmak)	10.77%	1.11

7.	11	Sebiprox (Stiefel Laboratories Inc)	9.23%	0.98

8.		Кето Плюс (Glenmark Farmaceuticals Limited)	6.15%	0.69

9.	7	Фрідерм (Bayer)	6.15%	0.64

10.	~	TerbinaКод (ФітоБіоТехнології)	4.62%	0.52

11.	9	Algopix (СЕБ-Фармація)	3.08%	0.35

12.	10	Ebersept (PharmUnion)	1.54%	0.17

The participant which took the 1st place in this rating is by opinion of Ukrainian consumers is the best choice in 2017, recommendation of consumers #1 in the category “The drug for treatment of the dandruff”.

Using this rating is only possible with obligatory link to the source.

This rating was built as a result of the study of social preferences in 2017, under the “Favorites of Success” Contest in Ukraine and it’s the free information. In case of full or partial republishing of the information drawn from this rating, it is obligatory to mention the name of the “Favorites of Success” Contest in printed publications, or put an active hyperlink to this page in the electronic media.

Advanced reporting booklet about the study, including demographics of the respondents, by regional breakdown, information roll-call of ad hoc judges etc, can also be obtained from managers of the contest.